You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

361 Results
Guidelines and Advice
Status: Current
ID: GL 8-10
Version: N/A
Feb 2020
Document
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Document
Apr 2020
Cette page s’adresse aux personnes ayant récemment reçu un diagnostic de leucémie aiguë lymphoblastique (LAL)
 
Document
Sep 2020
Document
Sep 2020

Pages